Neogen Corporation, together with its subsidiaries, develops, manufactures, and markets various products for food and animal safety worldwide. It operates through two segments, Food Safety and Animal Safety. The Food Safety segment offers diagnostic test kits and related products to detect dangerous and unintended substances in food and animal feed, including foodborne pathogens, spoilage organisms, natural toxins, food allergens, genetic modifications, ruminant by-products, meat speciation, drug residues, pesticide residues, and general sanitation concerns; and AccuPoint Advanced rapid sanitation test for adenosine triphosphate, a chemical found in living cells. This segment offers its products primarily to food and feed processors; grain producers and processors; producers of cookies, crackers, candy, ice cream, and other processed foods; meat and poultry processors, seafood processors, fruit and vegetable producers, and dairies; laboratories; and producers of pharmaceuticals, cosmetics, veterinary vaccines, and nutraceutical products. The Animal Safety segment provides veterinary instruments, pharmaceuticals, vaccines, topicals, diagnostic products, rodenticides, cleaners, disinfectants, insecticides, and genomics testing services for the animal safety market. This segment offers various products for researchers to detect biologically active substances. Its drug detection immunoassay test kits are used for the detection of abused and therapeutic drugs in farm and racing animals; detection of drug residues in meat and meat products; and human forensic toxicology drug screening applications. In addition, this segment's products are also used to maintain sanitary conditions and limit the potential hazards of bacteria, fungi, and viruses. The company sells its products directly, as well as through distributors and retail chains. Neogen Corporation was founded in 1981 and is headquartered in Lansing, Michigan.
IPO Year: 1989
Exchange: NASDAQ
Website: neogen.com
Date | Price Target | Rating | Analyst |
---|---|---|---|
12/19/2024 | $15.00 | Buy | Guggenheim |
6/16/2023 | $22.00 | Overweight | Wells Fargo |
11/22/2022 | Mkt Perform → Outperform | William Blair | |
7/12/2022 | $25.00 | Neutral | Piper Sandler |
4 - NEOGEN CORP (0000711377) (Issuer)
3 - NEOGEN CORP (0000711377) (Issuer)
4 - NEOGEN CORP (0000711377) (Issuer)
4 - NEOGEN CORP (0000711377) (Issuer)
4 - NEOGEN CORP (0000711377) (Issuer)
4 - NEOGEN CORP (0000711377) (Issuer)
4 - NEOGEN CORP (0000711377) (Issuer)
4 - NEOGEN CORP (0000711377) (Issuer)
4 - NEOGEN CORP (0000711377) (Issuer)
4 - NEOGEN CORP (0000711377) (Issuer)
Guggenheim initiated coverage of Neogen with a rating of Buy and set a new price target of $15.00
Wells Fargo initiated coverage of Neogen with a rating of Overweight and set a new price target of $22.00
William Blair upgraded Neogen from Mkt Perform to Outperform
Piper Sandler initiated coverage of Neogen with a rating of Neutral and set a new price target of $25.00